Castle Biosciences, Inc. (CSTL) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $24.80 (+1.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 29, 2026 | Paul Knight | KeyBanc | $50.00 | +101.6% |
| Jan 26, 2026 | Subbu Nambi | Guggenheim | $47.00 | +89.5% |
| Dec 12, 2025 | Mark Massaro | BTIG | $50.00 | +101.6% |
| Mar 28, 2025 | Subbu Nambi | Guggenheim | $30.00 | +21.0% |
| Nov 5, 2024 | Sung Ji Nam | BTIG | $45.00 | +81.5% |
| Nov 5, 2024 | Catherine Schulte | Robert W. Baird | $39.00 | +57.3% |
| Nov 5, 2024 | Paul Knight | KeyBanc | $36.00 | +45.2% |
| Oct 29, 2024 | Kyle Mikson | Canaccord Genuity | $42.00 | +69.4% |
| Oct 14, 2024 | Sung Ji Nam | BTIG | $40.00 | +61.3% |
| Aug 6, 2024 | Sung Ji Nam | BTIG | $35.00 | +41.1% |
| Nov 4, 2022 | Catherine Schulte Analyst | Robert W. Baird | $41.00 | +65.3% |
Top Analysts Covering CSTL
CSTL vs Sector & Market
| Metric | CSTL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 9 | 8 | 18 |
| Target Upside | +92.7% | +1150.2% | +14.9% |
| P/E Ratio | -29.99 | 6.90 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $83M | $86M | $89M | 5 |
| 2026-09-30 | $87M | $90M | $92M | 2 |
| 2026-12-31 | $89M | $91M | $93M | 2 |
| 2027-03-31 | $87M | $90M | $92M | 2 |
| 2027-06-30 | $94M | $97M | $99M | 2 |
| 2027-09-30 | $98M | $101M | $103M | 2 |
| 2027-12-31 | $100M | $103M | $105M | 2 |
| 2028-12-31 | $432M | $434M | $438M | 5 |
| 2029-12-31 | $464M | $467M | $471M | 2 |
| 2030-12-31 | $503M | $506M | $510M | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.32 | $-0.31 | $-0.30 | 4 |
| 2026-09-30 | $-0.20 | $-0.19 | $-0.18 | 1 |
| 2026-12-31 | $-0.20 | $-0.19 | $-0.18 | 2 |
| 2027-03-31 | $-0.35 | $-0.34 | $-0.33 | 2 |
| 2027-06-30 | $-0.17 | $-0.16 | $-0.16 | 1 |
| 2027-09-30 | $-0.05 | $-0.04 | $-0.04 | 1 |
| 2027-12-31 | $-0.02 | $-0.02 | $-0.02 | 2 |
| 2028-12-31 | $-0.35 | $-0.03 | $0.31 | 5 |
| 2029-12-31 | $0.56 | $0.56 | $0.57 | 1 |
| 2030-12-31 | $1.01 | $1.01 | $1.03 | 1 |
Frequently Asked Questions
What is the analyst consensus for CSTL?
The consensus among 9 analysts covering Castle Biosciences, Inc. (CSTL) is Buy with an average price target of $49.80.
What is the highest price target for CSTL?
The highest price target for CSTL is $50.00, set by Paul Knight at KeyBanc on 2026-01-29.
What is the lowest price target for CSTL?
The lowest price target for CSTL is $30.00, set by Subbu Nambi at Guggenheim on 2025-03-28.
How many analysts cover CSTL?
9 analysts have issued ratings for Castle Biosciences, Inc. in the past 12 months.
Is CSTL a buy or sell right now?
Based on 9 analyst ratings, CSTL has a consensus rating of Buy (2.00/5) with a +92.7% upside to the consensus target of $49.80.
What are the earnings estimates for CSTL?
Analysts estimate CSTL will report EPS of $-0.31 for the period ending 2026-06-30, with revenue estimated at $86M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.